Dr. Jeffrey Weber on Ipilimumab for Melanoma

Jeffrey S. Weber, MD, PhD
Published: Monday, Feb 02, 2015



Jeffrey Weber, MD, PhD, a senior member at the Moffitt Cancer Center, discusses the EORTC 18701 study, which compared ipilimumab with placebo for patients with stage III node-positive melanoma.
The data were impressive, says Weber. The study showed that there was a clear benefit in terms of relapse-free survival (RFS) for the patients on the ipilimumab arm.
The median follow-up was 2.7 years, and RFS rates were 46.5% with ipilimumab versus 34.8% with placebo. The median RFS was 26.1 for ipilimumab versus 17.1 months for placebo.


Jeffrey Weber, MD, PhD, a senior member at the Moffitt Cancer Center, discusses the EORTC 18701 study, which compared ipilimumab with placebo for patients with stage III node-positive melanoma.
The data were impressive, says Weber. The study showed that there was a clear benefit in terms of relapse-free survival (RFS) for the patients on the ipilimumab arm.
The median follow-up was 2.7 years, and RFS rates were 46.5% with ipilimumab versus 34.8% with placebo. The median RFS was 26.1 for ipilimumab versus 17.1 months for placebo.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Publication Bottom Border
Border Publication
x